Publisher's Synopsis
NUCYNTA Drug Profile, 2024
This report focuses on NUCYNTA and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- Patent Trial and Appeal Board (PTAB) patent cases
- European supplementary protection certificates (SPCs)
- Clinical trials
- Drug prices
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
